NSPR vs. APYX, CTSO, DRIO, LUCD, XAIR, DXR, AMIX, ICCM, GBS, and HSAQ
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include Apyx Medical (APYX), Cytosorbents (CTSO), DarioHealth (DRIO), Lucid Diagnostics (LUCD), Beyond Air (XAIR), Daxor (DXR), Autonomix Medical (AMIX), IceCure Medical (ICCM), GBS (GBS), and Health Sciences Acquisitions Co. 2 (HSAQ). These companies are all part of the "surgical & medical instruments" industry.
Apyx Medical (NASDAQ:APYX) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
In the previous week, Apyx Medical had 2 more articles in the media than InspireMD. MarketBeat recorded 9 mentions for Apyx Medical and 7 mentions for InspireMD. InspireMD's average media sentiment score of 0.08 beat Apyx Medical's score of -0.76 indicating that Apyx Medical is being referred to more favorably in the media.
Apyx Medical has higher revenue and earnings than InspireMD. Apyx Medical is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Apyx Medical received 75 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 61.60% of users gave Apyx Medical an outperform vote while only 3.85% of users gave InspireMD an outperform vote.
55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 13.1% of Apyx Medical shares are held by company insiders. Comparatively, 29.7% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Apyx Medical has a net margin of -45.20% compared to Apyx Medical's net margin of -320.97%. Apyx Medical's return on equity of -55.71% beat InspireMD's return on equity.
Apyx Medical has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Apyx Medical currently has a consensus price target of $6.17, suggesting a potential upside of 303.05%. InspireMD has a consensus price target of $4.85, suggesting a potential upside of 110.87%. Given InspireMD's higher possible upside, equities analysts plainly believe Apyx Medical is more favorable than InspireMD.
Summary
Apyx Medical beats InspireMD on 13 of the 17 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
